In the United States, Moderna announced that the Food and Drug Administration (FDA) has formally refused to review its application for a new flu vaccine utilizing mRNA technology, which is known for winning a Nobel Prize. This letter, termed a 'refusal-to-file' letter, objected to the manner in which Moderna conducted its extensive clinical trial. This trial involved 40,000 participants and aimed at measuring the efficacy of the vaccine compared to a standard flu shot. Although the results indicated that the new vaccine was somewhat more effective for adults aged 50 and above, the FDA raised concerns regarding the validity of the trial. Specifically, the FDA argued that the comparison was not made against what it deemed the best-available standard of care at the time the study was conducted. Dr. Vinay Prasad, director of the FDA's vaccine division, critiqued the trial execution in his correspondence with Moderna, referencing specific guidance provided under the previous administration, which Moderna opted not to follow. Though the trial proceeded with the FDA's approval, the agency pointed out that a different, brand of flu shot specifically recommended for seniors would have been more appropriate for participants aged 65 and older. Furthermore, Moderna had shared supplementary data from another trial that involved comparisons against a licensed high-dose flu shot for seniors, but the FDA did not raise any issues concerning safety or efficacy in their product assessments. This rare refusal from the FDA highlights the increasing scrutiny towards mRNA vaccines under the leadership of Health Secretary Robert F. Kennedy Jr. Since taking office, Kennedy has implemented changes in vaccine oversight, including the removal of officials who opposed the administration's stance. Additionally, the FDA has intensified its critical approach toward vaccines, rolling back past recommendations concerning COVID-19 vaccines and has halted long-standing practices that facilitated quicker updates for flu shots targeting the latest strains. Moderna has expressed disappointment, arguing that the FDA's actions do not align with the mutual objective to enhance the nation’s position in innovative medicine development. Moderna has also sought an urgent meeting with the FDA regarding this matter while pursuing approval for the same vaccine in Europe, Canada, and Australia.